Match Document Document Title
US20140037728 DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME  
The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The...
US20120128771 TIMED, PULSATILE RELEASE SYSTEMS  
A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles...
US20140112984 Crush resistant delayed-release dosage forms  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20110002989 METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD  
The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment,...
US20130059000 ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS  
A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three...
US20110123618 Controlled release formulation of lamotrigine  
Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the...
US20110287100 Galenic Formulations of Organic Compounds  
A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount...
US20100297224 NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use  
The present invention generally relates to pharmaceutical unit dosage forms of NSAIDs and H2-receptor antagonists, in which the H2-receptor antagonist is formulated so as to be released in a...
US20130224292 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20110081412 ORALLY DISINTEGRABLE TABLETS  
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated...
US20150216810 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
US20150216809 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
US20140377348 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
US20140112981 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
US20140271852 SUSTAINED RELEASE FORMULATION OF NALBUPHINE  
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts...
US20150017241 ORAL FORMULATIONS OF DEFERASIROX  
Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
US20130287848 Bromocriptine Formulations  
The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic...
US20110300217 HYDROMORPHONE THERAPY  
A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
US20140212488 ORAL TABLET FORMULATION CONSISTING OF IMMEDIATE RELEASE ROSUVASTATIN AND EXTENDED RELEASE METFORMIN  
A solid dosage product and formulation containing a fixed combination of rosuvastatin and metformin is provided here. In the formulation rosuvastatin is delivered immediately to the patient and...
US20140112985 METHOD OF PREVENTION AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION  
This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its...
US20110091548 USE OF A MATRIX FOR ORALLY ADMINISTERING SUSTAINED RELEASE MAGNESIUM, AND COMPOSITION CONTAINING SAID MATRIX  
A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to...
US20140322322 COMPOSITION COMPRISING SOLANUM GLAUCOPHYLLUM FOR PREVENTING AND/OR TREATING HYPOCALCAEMIA AND FOR STABILIZING BLOOD CALCIUM LEVELS  
The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a Solarium glaucophyllum preparation. The composition further preferably...
US20140322321 TABLET CAPABLE OF COMBATTING MISUSE BY INJECTION  
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible...
US20110268795 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions  
The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release...
US20140147499 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20140302125 Methods for treating cardiovascular disorders  
There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of...
US20130011478 PHARMACOLOGICALLY OPTIMIZED MULTIMODAL DRUG DELIVERY SYSTEM FOR NORDIHYDROGUIARETIC ACID (NDGA)  
The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically...
US20100015222 GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC  
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage...
US20110052685 GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN  
Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon...
US20140037729 COMBINATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST IN THE TREATMENT OF PARKINSON'S DISEASE  
The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers...
US20110142905 COATED TABLETS WITH REMAINING DEGRADATION SURFACE OVER THE TIME  
The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet,...
US20100330172 CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION  
A pharmaceutical formulation comprising desvenlafaxine having an MMD of between about 5 μm and about 100 μm, or a pharmaceutically acceptable salt thereof, and at least one matrix rate-controlling...
US20140242168 SWELLABLE COATED TABLET  
The present invention provides perorally administrable drug release systems and processes for producing perorally administrable systems having a drug-containing core and a sheath which surrounds...
US20140141079 PRAMIPEXOLE ONCE-DAILY DOSAGE FORM  
An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically...
US20130108697 MODIFIED RELEASE DOSAGE FORM  
There is provided a modified release dosage form comprising a core coated with a polymeric coat, said polymeric coat comprising one or more rate controlling polymers, said dosage form having a...
US20110159088 ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS  
The field of the present invention is that of oral pharmaceutical forms of at least one active principle AP whose solubility varies greatly as a function of the gastric pH, and also treatments and...
US20150072005 ASPIRIN FORMULATION FOR INCREASED EFFICACY  
Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof....
US20150030677 Tamper Resistant Immediate Release Formulations  
Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;
US20130034604 EXTENDED RELEASE FORMULATIONS OF DESVENLAFAXINE BASE  
An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An...
US20070281018 SUSTAINED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS  
The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods...
US20150030675 Controlled Release Dosage Forms  
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°...
US20140147500 Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems  
Pharmaceutical compositions comprising one or more digestive enzymes and one or more gastrointestinal modulators of acid are provided. The one or more digestive enzymes may be coated, e.g., with a...
US20120141583 ALCOHOL RESISTANT DOSAGE FORMS  
Opioid controlled release formulation resistant to alcohol extraction of the opioid.
US20120171287 OSMOTIC PUMP CONTROLLED RELEASE TABLET AND PREPARATION METHOD THEREOF  
An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and...
US20110200671 METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY  
The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release...
US20130315994 MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT  
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline...
US20110212174 CONTROLLED RELEASE ARGININE FORMULATIONS  
A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic...
US20140170217 COMBINATION COMPOSITION COMPRISING OXYCODONE AND ACETAMINOPHEN FOR RAPID ONSET AND EXTENDED DURATION OF ANALGESIA  
The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen...
US20110059169 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20060165790 Multiparticulates  
Multipartulates of oxycodone can be made by extrusion of a blend which suitably contains (a) oxycodone, (b) water-insoluble ammonium methacrylate copolymer, (c) plasticiser, (d) lubricant and (e)...